The goal of the Genomics Core is to provide comprehensive support for genomic analyses carried out in each of the Case Gl SPORE Projects. The Genomics Core will capitalize on the significant investment in common and shared infrastructure that has been created at CWRU, with support from the School of Medicine, the Case Comprehensive Cancer Center, and the Howard Hughes Medical Institute. CWRU and Cancer Center core resources that are part of this SPORE have been the subject of NIH support and are partially funded as such;thus, this SPORE will be leveraging the existing support to provide each project access to state-of-the-art genome-scale analysis expertise. The Genomics Core builds on exisfing core facilities that have a significant track record of performance and success, as well as the faculty interactions which have supported the initial work for components presented within each Project of this application. The Genomics Core will be a central resource for providing high-throughput genotyping and 'next-generation' DNA sequencing capability for two Projects. In addition, the Core will develop and implement additional methods as necessary to support all Projects, including Pilot Projects. The equipment and personnel available in the Genomics Core support research activities that require instrumentation and expertise that are not available or practical in the laboratories of the individual Project Pis, and for which centralized analyses are required in order to achieve process standardization and economies-of-scale. Specifically, the Genomics Core will perform region-specific DNA capture and high-throughput DNA sequencing and genotyping in support of the individual SPORE Projects. The Genomics Core will work closely with the Specimen and Tissue Core for access to quality assessment of materials for analysis and with the Biostatistics Core for data quality assessment and analysis.

Agency
National Institute of Health (NIH)
Type
Specialized Center (P50)
Project #
5P50CA150964-04
Application #
8711350
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Kendall, Bradley J; Rubenstein, Joel H; Cook, Michael B et al. (2016) Inverse Association Between Gluteofemoral Obesity and Risk of Barrett's Esophagus in a Pooled Analysis. Clin Gastroenterol Hepatol 14:1412-1419.e3
Thota, Prashanthi N; Zackria, Shamiq; Sanaka, Madhusudhan R et al. (2016) Racial Disparity in the Sex Distribution, the Prevalence, and the Incidence of Dysplasia in Barrett's Esophagus. J Clin Gastroenterol :
Parameswaran, Reshmi; Ramakrishnan, Parameswaran; Moreton, Stephen A et al. (2016) Repression of GSK3 restores NK cell cytotoxicity in AML patients. Nat Commun 7:11154
Peyser, Noah D; Wang, Lin; Zeng, Yan et al. (2016) STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma. Cancer Prev Res (Phila) 9:657-63
Cui, Min; Awadallah, Amad; Liu, Wendy et al. (2016) Loss of Hes1 Differentiates Sessile Serrated Adenoma/Polyp From Hyperplastic Polyp. Am J Surg Pathol 40:113-9
Venkitachalam, Srividya; Revoredo, Leslie; Varadan, Vinay et al. (2016) Biochemical and functional characterization of glycosylation-associated mutational landscapes in colon cancer. Sci Rep 6:23642
Fecteau, Ryan E; Kong, Jianping; Kresak, Adam et al. (2016) Association Between Germline Mutation in VSIG10L and Familial Barrett Neoplasia. JAMA Oncol 2:1333-1339
Sun, Xiangqing; Elston, Robert C; Barnholtz-Sloan, Jill S et al. (2016) Predicting Barrett's Esophagus in Families: An Esophagus Translational Research Network (BETRNet) Model Fitting Clinical Data to a Familial Paradigm. Cancer Epidemiol Biomarkers Prev 25:727-35
Russo, Suzanne; Ammori, John; Eads, Jennifer et al. (2016) The role of neoadjuvant therapy in pancreatic cancer: a review. Future Oncol 12:669-85
Eads, Jennifer R; Beumer, Jan H; Negrea, Lavinia et al. (2016) A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis. Cancer Chemother Pharmacol 77:333-8

Showing the most recent 10 out of 118 publications